Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0169-5002(93)90233-nPMID 7677981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells Review

  2004influential reference
• Chemotherapy of small cell lung cancer.

  1991cited by this paper
• Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer.

  1991cited by this paper
• Phase II study of alternating combination chemotherapy in small cell lung cancer

  1991cited by this paper
• Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.

  1990cited by this paper
• Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

  1990cited by this paper
• Lung cancer.

  1990cited by this paper
• An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research.

  1990cited by this paper
• Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features.

  1989cited by this paper
• Serum lactate dehydrogenase in small-cell lung cancer.

  1989cited by this paper
• Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.

  1989cited by this paper
• The prognostic influence of serum neuron specific enolase in small cell lung cancer.

  1988cited by this paper
• Ploidy as a prognostic determinant in surgically treated lung cancer.

  1987cited by this paper
• Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression.

  1987cited by this paper
• Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens.

  1987cited by this paper
• Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.

  1986cited by this paper
• Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

  1986cited by this paper
• The use of relative operating characteristic (ROC) curves in test performance evaluation.

  1986cited by this paper
• Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma

  1986cited by this paper
• Small cell lung cancer.

  1986cited by this paper
• Treatment of non-small-cell lung cancer.

  1986cited by this paper
• Klaas Breur Medal lecture 1985. The growth and progression of human tumors: implications for management strategy.

  1986cited by this paper
• Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage.

  1985cited by this paper
• Differential expression of intermediate filament proteins distinguishes classic from variant small-cell lung cancer cell lines.

  1985cited by this paper
• Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group

  1984cited by this paper
• Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies.

  1984cited by this paper
• Cytokeratin and neurofilament in lung carcinomas.

  1984cited by this paper
• Staging and prognostic factors in small cell carcinoma of the lung.

  1983cited by this paper
• Intermediate filaments: cell-type-specific markers in differentiation and pathology.

  1982cited by this paper
• Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung.

  1982cited by this paper
• The Etiology, Epidemiology, and Prevention of Lung Cancer

  1982cited by this paper
• Complex cytokeratin polypeptide patterns observed in certain human carcinomas.

  1982cited by this paper
• The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.

  1982cited by this paper
• Causes of treatment failure and death in carcinoma of the lung.

  1981cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals

  2025cites this paper
• Development and validation of a multimodal radiomics-serum biomarker model for diagnosing solid pulmonary nodules via machine learning

  2025cites this paper
• A deeper evaluation of cytokeratin fragment 21–1 as a lung cancer tumor marker and comparison of different assays

  2025cites this paper
• Development of a Clinical Prediction Model to Predict Malignant Transformation of Sinonasal Inverted Papilloma Based on Hematological Indices and Clinical Features

  2025cites this paper
• Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study

  2025cites this paper
• Ultra-sensitive graphene-based toroidal dipole meta-biosensor for trace detection of protein biomarkers in the terahertz band

  2025cites this paper
• Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer

  2024cites this paper
• Washout CYFRA 21-1: A tool to improve diagnostic accuracy of fine needle aspiration in the diagnosis of metastatic lymph nodes in papillary thyroid cancer

  2024cites this paper
• Diagnostic utilities of washout CYFRA 21-1 combined with washout thyroglobulin for metastatic lymph nodes in thyroid cancer: a prospective study

  2024cites this paper
• Variability of serum CYFRA 21 − 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis

  2023cites this paper
• Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression

  2023cites this paper
• Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs

  2023cites this paper
• Detection of CYFRA21-1 in serum by electrochemical immunosensor based on nanocomposite consisting of AuNPs@CMK-3@CMWCNTs.

  2022cites this paper
• Age and Smoking Status Affect Serum Cytokeratin 19 Fragment Levels in Individuals Without Cancer

  2022cites this paper
• Diagnostic of Cytokeratin-19 Gene Expression in Iranian Breast Cancer Patients.

  2022cites this paper
• Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma

  2022cites this paper
• A new strategy to design label-free electrochemical biosensor for ultrasensitive diagnosis of CYFRA 21-1 as a biomarker for detection of non-small cell lung cancer.

  2022cites this paper
• AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study

  2022cites this paper
• Impedimetric immunosensors for detection of biomarkers

  2022cites this paper
• Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis

  2021cites this paper
• Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy

  2021cites this paper
• Carcinoma of unknown primary origin with isolated adrenal metastasis: a report of two cases.

  2021cites this paper
• Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review

  2021cites this paper
• Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer

  2021cites this paper
• Biomarkers and diagnostic tools for lung cancer

  2021cites this paper
• Reproductive Organ Cancer

  2021cites this paper
• The diagnostic significance of circulating lncRNA ADAMTS9‐AS2 tumor biomarker in non‐small cell lung cancer among the Egyptian population

  2021cites this paper
• Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.

  2021cites this paper
• Biomarkers of Lung Cancer: Meta-analysis of Biomarkers Used to Identify Types of Lung Cancers Based on the Morphology and Histology

  2021influential citation
• Prognostic significance of KRT19 in Lung Squamous Cancer

  2021cites this paper
• Elevated serum CYFRA 21‐1 level as a diagnostic marker for thymic carcinoma

  2021cites this paper
• Sensitive electrochemical immunosensor for CYFRA21-1 detection based on AuNPs@MoS2@Ti3C2Tx composites.

  2021cites this paper
• Clinical relevance of CYFRA 21-1 as a tumour marker in patients with oropharyngeal squamous cell carcinoma

  2020cites this paper
• Alterations in serum protein glycopatterns related to small cell lung cancer, adenocarcinoma and squamous carcinoma of the lung

  2020cites this paper
• CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype

  2020cites this paper
• Keratin intermediate filaments in the colon: guardians of epithelial homeostasis.

  2020cites this paper
• Recent progress on developing of plasmon biosensing of tumor biomarkers: Efficient method towards early stage recognition of cancer.

  2020cites this paper
• Cytokeratin 19 as a biomarker of highly invasive oral squamous cell carcinoma with metastatic potential

  2020cites this paper
• Biochemical analysis of cytokeratin fragment 21-1 concentration and expression of cytokeratin 19 in oral potentially malignant disorders

  2020cites this paper
• Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China

  2020cites this paper
• CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?

  2019cites this paper
• Identification of lung cancer gene markers through kernel maximum mean discrepancy and information entropy

  2019cites this paper
• CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis

  2019cites this paper
• Prognostic Value of the Tumor Marker Index Based on Preoperative Serum Carcinoembryon-ic Antigen and Cytokeratin-19 Fragment Levels for Overall and Disease-Free Survival in Patients with Stage I Non-Small Cell Lung Cancer

  2019cites this paper
• CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis

  2019cites this paper
• Dual signal amplification by polysaccharide and eATRP for ultrasensitive detection of CYFRA 21-1 DNA.

  2019cites this paper
• Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.

  2019cites this paper
• Relevance of Circulating Tumor Cells , Extracellular Nucleic Acids and Exosomes in 1 Breast Cancer 2 3

  2019cites this paper
• The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy

  2019cites this paper
• Bioinspired biomaterials and enzyme-based biosensors for point-of-care applications with reference to cancer and bio-imaging

  2019cites this paper
• TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer

  2018cites this paper
• Diagnostic and Prognostic Value of Serum Cyfra 21–1 Levels in Patients with Pancreatic Cancer

  2018cites this paper
• Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy

  2018cites this paper
• Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer

  2018cites this paper
• The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC).

  2018cites this paper
• A sandwich-type electrochemical immunoassay for ultrasensitive detection of non-small cell lung cancer biomarker CYFRA21-1.

  2018cites this paper
• Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer

  2018cites this paper
• Circulating Mucins and Cytokeratins in Aggressive Thyroid Cancers

  2018cites this paper
• Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.

  2017cites this paper
• Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease

  2017cites this paper
• The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

  2017cites this paper
• Current and Prospective Protein Biomarkers of Lung Cancer

  2017cites this paper
• CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.

  2017cites this paper
• Tumor Markers in Head and Neck Cancer

  2017cites this paper
• Identification of keratin 19‐positive cancer stem cells associating human hepatocellular carcinoma using CYFRA 21‐1

  2017cites this paper
• History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer

  2017influential citation
• Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples

  2017cites this paper
• Serum Cyfra 21-1 levels in oral squamous cell carcinoma patients and its clinicopathologic correlation

  2017cites this paper
• Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer

  2017cites this paper
• Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling

  2016cites this paper
• Immunohistochemical pattern analysis of squamous cell carcinoma: Lung primary and metastatic tumors of head and neck.

  2016cites this paper
• Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study.

  2016cites this paper
• Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma

  2016cites this paper
• Gene expression of cytokeratin 19 and its molecular detection in human breast cancer cell lines.

  2016cites this paper
• Study of CAPE effect on apoptosis induction in AGS human gastric cancer cell line

  2016cites this paper
• Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer

  2015cites this paper
• Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma.

  2015cites this paper
• Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer

  2015cites this paper
• Diagnostic Utility of Serum Cytokeratin Fragment 21-1 in Patients with Lung Cancer

  2015cites this paper
• Prognostic Value of CYFRA 21-1 and Carcinoembryonic Antigen in Non-Small Cell Lung Cancer

  2015cites this paper
• Cervical cancer: Biomarkers for diagnosis and treatment.

  2015cites this paper
• Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer

  2015influential citation
• Thymoma exhibiting spontaneous regression in size, pleural effusion and serum cytokeratin fragment level: A case report.

  2015cites this paper
• CK19 is a sensitive marker for yolk sac tumours of the testis

  2015cites this paper
• A Magnetic Nanoparticle-Based Time-Resolved Fluoroimmunoassay for Determination of the Cytokeratin 19 Fragment in Human Serum

  2015cites this paper
• Label-free detection of tumor markers using field effect transistor (FET)-based biosensors for lung cancer diagnosis

  2015cites this paper
• Cancer Biomarker Discovery Using N-terminal Peptides and Multiple Reaction Monitoring-MS Techniques

  2015cites this paper
• Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer

  2014cites this paper
• Keratin 19 expression correlates with poor prognosis in breast cancer

  2014cites this paper
• Determination of the best prognostic value of serum tumor markers in patients with suspected lung cancer in an Iranian population.

  2014cites this paper
• Cytokeratin-19 as a biomarker in urine and in serum for the diagnosis of endometriosis – a prospective study

  2014cites this paper
• Label-Free Quantitative Proteomics and N-terminal Analysis of Human Metastatic Lung Cancer Cells

  2014cites this paper
• Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment.

  2014cites this paper
• Biomarkers for virus-induced hepatocellular carcinoma (HCC).

  2014cites this paper
• Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer.

  2014cites this paper
• Serum Cytokeratin 19 Fragment, CK19-2G2, as a Newly Identified Biomarker for Lung Cancer

  2014cites this paper
• Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer.

  2014cites this paper
• Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers

  2013cites this paper
• Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation

  2013cites this paper
• A Novel Immunoassay for the Quantization of CYFRA 21–1 in Human Serum

  2013cites this paper